In this regard, it is noteworthy that some CTLA-4 SNVs, including CT60G>A, did not show any significant effect in melanoma patients treated with adjuvant interferon alpha therapy (25), thus supporting the hypothesis of some involvement of determined SNVs in CTLA-4-based immunotherapy. Here, CTLA4 is linked to melanoma.